Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 9.59% is 227% above its 5-year average of -7.56%, near the high end of its 5-year range (-539.50%–226.05%).
3.28% below its 12-month average of 9.91%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10.44%.
NET PROFIT MARGIN
9.59%
NET PROFIT MARGIN AVG TTM
9.91%
NET PROFIT MARGIN AVG 3Y
3.23%
NET PROFIT MARGIN AVG 5Y
-7.56%
NET PROFIT MARGIN AVG 10Y
0.63%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3.28%
CURRENT VS 3Y AVG
+196.94%
CURRENT VS 5Y AVG
+226.79%
CURRENT VS 10Y AVG
+1419.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 612 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Kiniksa Pharmaceuticals International, plc
Market Cap
$5.63B
Net Profit Margin
9.59%
TTM Avg
9.91%
3Y Avg
3.23%
5Y Avg
-7.56%
Market Cap
$5.70B
Net Profit Margin
-3602.68%
TTM Avg
-5857.26%
3Y Avg
-13524.50%
5Y Avg
-10844.39%
Market Cap
$5.54B
Net Profit Margin
-10.21%
TTM Avg
-9.94%
3Y Avg
-7.18%
5Y Avg
-7.18%
Market Cap
$5.82B
Net Profit Margin
-89.09%
TTM Avg
-187.61%
3Y Avg
-9430.16%
5Y Avg
-6286.77%
Market Cap
$5.36B
Net Profit Margin
25.48%
TTM Avg
34.77%
3Y Avg
31.87%
5Y Avg
32.80%
Market Cap
$5.94B
Net Profit Margin
67.88%
TTM Avg
22.01%
3Y Avg
16.68%
5Y Avg
14.76%
Market Cap
$6.00B
Net Profit Margin
-236.95%
TTM Avg
-945.70%
3Y Avg
-3296.24%
5Y Avg
-3620.73%
Market Cap
$5.22B
Net Profit Margin
-3368.72%
TTM Avg
-8808.10%
3Y Avg
-41695.11%
5Y Avg
-35876.65%
Market Cap
$5.13B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-158.41%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | $5.63B | 9.59% | 9.91% | 3.23% | -7.56% |
| CG Oncology Inc. (CGON)vs › | $5.70B | -3602.68% | -5857.26% | -13524.50% | -10844.39% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | -10.21% | -9.94% | -7.18% | -7.18% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.82B | -89.09% | -187.61% | -9430.16% | -6286.77% |
| Doximity, Inc. (DOCS)vs › | $5.36B | 25.48% | 34.77% | 31.87% | 32.80% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 67.88% | 22.01% | 16.68% | 14.76% |
| GRAIL Inc. (GRAL)vs › | $6.00B | -236.95% | -945.70% | -3296.24% | -3620.73% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.22B | -3368.72% | -8808.10% | -41695.11% | -35876.65% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.13B | 0.00% | 0.00% | 0.00% | -158.41% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 9.22% | 8.68% | 7.83% | 5.80% |
Operating Margin
11.9%
Net Profit Margin
9.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 10.44% |
| 2026-03-31 | 10.54% |
| 2025-12-31 | 7.02% |
| 2025-09-30 | 10.19% |
| 2025-06-30 | 11.37% |
| 2025-03-31 | 6.20% |
| 2024-12-31 | -7.25% |
| 2024-09-30 | -11.31% |
| 2024-06-30 | -3.60% |
| 2024-03-31 | -22.17% |
| 2023-12-31 | 30.26% |
| 2023-09-30 | -20.66% |
| 2023-06-30 | 20.95% |
| 2023-03-31 | -25.38% |
| 2022-12-31 | 7.21% |
| 2022-09-30 | 226.05% |
| 2022-06-30 | -74.08% |
| 2022-03-31 | -78.32% |
| 2021-12-31 | -193.83% |
| 2021-09-30 | -252.53% |
| 2021-06-30 | -539.50% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
